Product
Necitumumab
Aliases
Anti-Epidermal Growth Factor Receptor Monoclonal Antibody IMC-11F8, IMC-11F8, LY3012211, Portrazza
Name
Portrazza
INN Name
necitumumab
FDA Approved
Yes
5 clinical trials
1 organization
7 indications
1 document
Indication
Lung CancerIndication
Metastatic Lung Non-Small Cell CarcinomaIndication
Refractory Non-Small Cell Lung CarcinomaIndication
Lung Cancer Stage IVA AJCC v8Indication
Recurrent Lung Non-Small Cell CarcinomaIndication
Stage IV Lung CancerIndication
NSCLCClinical trial
A Randomized, Multicenter, Open-Label Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)Status: Active (not recruiting), Estimated PCD: 2013-06-17
Clinical trial
An Open-Label, Multicenter, Phase 1 Study With Expansion Cohorts of Ramucirumab or Necitumumab in Combination With Osimertinib in Patients With Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer After Progression on First-Line EGFR TKI TherapyStatus: Completed, Estimated PCD: 2017-10-19
Clinical trial
A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy.Status: Active (not recruiting), Estimated PCD: 2025-05-06
Clinical trial
UCLA L-08: A Phase Ib/II Study of Combined HER Inhibition Adding Necitumumab and Trastuzumab to Osimertinib in Patients With Refractory EGFR-Mutated Lung CancerStatus: Recruiting, Estimated PCD: 2024-12-02
Clinical trial
A Phase I Trial of Osimertinib (AZD9291) and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase InhibitorStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Document
DailyMed Label: PortrazzaOrganization
Eli Lilly and Company